A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Mise à jour : Il y a 4 ans
Référence : NCT00375674

Femme et Homme

Extrait

To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.


Critère d'inclusion

  • Kidney Neoplasms


Liens